您当前的位置：
首页 >
文章列表页 >
Economic evaluation of finotonlimab combined with bevacizumab as first-line treatment for advanced hepatocellular carcinoma
Drug and Clinical Practice | 更新时间：2026-10-28

    • Economic evaluation of finotonlimab combined with bevacizumab as first-line treatment for advanced hepatocellular carcinoma

    • Chin J Hosp Pharm   Vol. 46, Issue 17, Pages: 2019-2025(2026)

    • DOI：10.13286/j.1001-5213.2026.17.08    

      CLC： R979.1

    • Published：15 September 2026

    移动端阅览

  • YIN Antong,LI Jing,WANG Yahua,et al.Economic evaluation of finotonlimab combined with bevacizumab as first-line treatment for advanced hepatocellular carcinoma[J].Chin J Hosp Pharm,2026,46(17):2019-2025. DOI： 10.13286/j.1001-5213.2026.17.08.

  •  
  •  

0

Views

0

下载量

0

CSCD

Alert me when the article has been cited
提交
Tools
Download
Export Citation
Share
Add to favorites
Add to my album

Related Articles

Cost-utility evaluation of darolutamide for the treatment of metastatic hormone-sensitive prostate cancer
Cost-utility analysis of benmelstobart combined with anlotinib as first-line therapy for advanced clear cell renal cell carcinoma
Cost-utility analysis of ponatinib combined with chemotherapy as first-line treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia
Cost‑utility analysis of sugemalimab plus chemotherapy as first‑line treatment for advanced gastric cancer
Cost-utility analysis of socazolimab combined with first-line chemotherapy for extensive-stage small cell lung cancer

Related Author

WAN Ziming
CHEN Hao
MENG Nannan
DOU Lei
LI Shunping
GE Kunkun
ZHU Tongming
PAN Min

Related Institution

Center for Health Preference Research， Shandong University
Center for Health Management and Policy Research， Shandong University/Shandong Provincial Key New Think Tank
NHC Key Lab of Health Economics and Policy Research/Shandong University
Department of Social Medicine and Health Management， School of Public Health， Cheeloo College of Medicine， Shandong University
School of Pharmacy， Anhui University of Chinese Medicine
0